Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

11th Mar 2025 15:25

RNS Number : 2445A
Smith & Nephew Plc
11 March 2025
 

SMITH & NEPHEW PLC

 

11 March 2025

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

 

 

1. VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2020

 

On 11 March 2025, the Company received notification of the following transactions in US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") following the vesting of awards under the Smith & Nephew Global Share Plan 2020.

 

i. VESTING OF 2022 PERFORMANCE SHARE PROGRAMME AWARDS MADE UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020:

 

The awards were granted under the Global Share Plan 2020 on 20 May 2022, and vested on 9 March 2025 at 59.3% of target for PDMRs who were members of the Company's Executive Committee on the date of grant, and 78.1% for other PDMRs appointed to the Executive Committee subsequent to the date of grant. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares. The table below sets out the number of shares under award which vested. The remaining shares under award have lapsed.

 

The following relates to individuals included in the below notification:

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc ordinary shares of USD 0.20 each

 

Identification code

ISIN: GB0009223206

Nature of the transaction

Vesting of Smith & Nephew Global Share Plan 2020: Performance Share Programme awards granted on 20 May 2022, and subsequent sale of shares to cover tax liability

Date of Transaction

9 March 2025 (vesting) and 10 March 2025 (market sale)

Place of Transaction

London Stock Exchange (XLON)

 

 

 

Name

(Position)

 

Status

Price (£)

Volume

Aggregated information

Helen Barraclough

(Group General Counsel and Company Secretary)

PDMR

11.441599

 

18,951 (of which 8,939 were sold and 10,012 retained)

N/A Single Transaction

Paul Connolly

(President Global Operations)

PDMR

11.441599

 

23,831 (of which 8,143 were sold and 15,688 retained)

N/A Single Transaction

Phil Cowdy

(Chief Corporate Development and Corporate Affairs Officer)

PDMR

11.441599

 

20,420 (of which 9,632 were sold and 10,788 retained)

N/A Single Transaction

Craig Gaffin

(President, Global Orthopaedics)

PDMR

11.441599

 

10,859 (of which 3,232 were sold and 7,627 retained)

N/A Single Transaction

Mizanu Kebede

(Chief Quality & Regulatory Affairs Officer)

PDMR

11.441599

 

24,368 (of which 9,009 were sold and 15,359 retained)

N/A Single Transaction

Elga Lohler

(Chief HR Officer)

PDMR

11.441599

 

29,821 (of which 11,866 were sold and 17,955 retained)

N/A Single Transaction

Vasant Padmanabhan

(President Research & Development ENT)

PDMR

11.441599

 

29,009 (of which 10,772 were sold and 18,237 retained)

N/A Single Transaction

Alison Parkes

(Chief Compliance Officer)

 

PDMR

11.441599

 

7,010 (of which 2,854 were sold and 4,156 retained)

N/A Single Transaction

Scott Schaffner

(President Sports Medicine)

PDMR

11.441599

 

12,909 (of which 4,794 were sold and 8,115 retained)

N/A Single Transaction

 

All figures in these columns are stated to 6 decimal places where applicable.

 

 

ii. FINAL VESTING OF 2022 DEFERRED BONUS SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020:

 

The awards were granted under the Global Share Plan 2020 on 9 March 2022 with vesting in equal tranches on the first, second and third anniversary of grant. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.

 

The following relates to individuals included in the below notification:

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc ordinary shares of USD 0.20 each

 

Identification code

ISIN: GB0009223206

Nature of the transaction

Final vesting on 9 March 2025 of Deferred Bonus Share awards, granted on 9 March 2022 under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability

Date of Transaction

9 March 2025 (vesting) and 10 March 2025 (market sale)

Place of Transaction

London Stock Exchange (XLON)

 

Name

(Position)

 

Status

Price (£)

Volume

Aggregated information

Helen Barraclough

(Group General Counsel and Company Secretary)

PDMR

11.441599

 

1,815 (of which 857 were sold and 958 retained)

N/A Single Transaction

Phil Cowdy

(Chief Corporate Development and Corporate Affairs Officer)

PDMR

11.441599

2,976 (of which 1,404 were sold and 1,572 retained)

N/A Single Transaction

Craig Gaffin

(President, Global Orthopaedics)

PDMR

11.441599

896 (of which 267 were sold and 629 retained)

N/A Single Transaction

Mizanu Kebede

(Chief Quality & Regulatory Affairs Officer)

PDMR

11.441599

752 (of which 278 were sold and 474 retained)

N/A Single Transaction

Elga Lohler

(Chief HR Officer)

PDMR

11.441599

4,247 (of which 1,690 were sold and 2,557 retained)

N/A Single Transaction

Vasant Padmanabhan

(President Research & Development ENT)

PDMR

11.441599

3,436 (of which 1,276 were sold and 2,160 retained)

N/A Single Transaction

Scott Schaffner

(President Sports Medicine)

PDMR

11.441599

2,496 (of which 927 were sold and 1,569 retained)

N/A Single Transaction

All figures in these columns are stated to 6 decimal places where applicable.

 

iii.  PARTIAL VESTING OF 2023 DEFERRED BONUS SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020:

 

The awards were granted under the Global Share Plan 2020 on 9 March 2023 with vesting in equal tranches on the first, second and third anniversary of grant. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.

 

The following relates to individuals included in the below notification:

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc ordinary shares of USD 0.20 each

 

Identification code

ISIN: GB0009223206

Nature of the transaction

Partial vesting on 9 March 2025 of Deferred Bonus Share awards, granted on 9 March 2023 under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability

Date of Transaction

9 March 2025 (vesting) and 10 March 2025 (market sale)

Place of Transaction

London Stock Exchange (XLON)

 

Name

(Position)

 

Status

Price (£)

Volume

Aggregated information

Helen Barraclough

(Group General Counsel and Company Secretary)

PDMR

11.441599

1,761 (of which 830 were sold and 931 retained)

N/A Single Transaction

Paul Connolly

(President, Global Operations)

PDMR

11.441599

1,995 (of which 682 were sold and 1,313 retained)

N/A Single Transaction

Phil Cowdy

(Chief Corporate Development and Corporate Affairs Officer)

PDMR

11.441599

1,897 (of which 895 were sold and 1,002 retained)

N/A Single Transaction

Craig Gaffin

(President, Global Orthopaedics)

PDMR

11.441599

590 (of which 176 were sold and 414 retained)

N/A Single Transaction

Mizanu Kebede

(Chief Quality & Regulatory Affairs Officer)

PDMR

11.441599

2,040 (of which 755 were sold and 1,285 retained)

N/A Single Transaction

Elga Lohler

(Chief HR Officer)

PDMR

11.441599

2,985 (of which 1,187 were sold and 1,798 retained)

N/A Single Transaction

Vasant Padmanabhan

(President Research & Development ENT)

PDMR

11.441599

2,429 (of which 902 were sold and 1,527 retained)

N/A Single Transaction

Alison Parkes

(Chief Compliance Officer)

PDMR

11.441599

1,055 (of which 476 were sold and 579 retained)

N/A Single Transaction

Scott Schaffner

(President Sports Medicine)

PDMR

11.441599

975 (of which 362 were sold and 613 retained)

N/A Single Transaction

All figures in these columns are stated to 6 decimal places where applicable.

 

iv.  PARTIAL VESTING OF 2024 DEFERRED BONUS SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020:

 

The awards were granted under the Global Share Plan 2020 on 8 March 2024 with vesting in equal tranches on the first, second and third anniversary of grant. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.

 

The following relates to individuals included in the below notification:

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc ordinary shares of USD 0.20 each

 

Identification code

ISIN: GB0009223206

Nature of the transaction

Partial vesting on 8 March 2025 of Deferred Bonus Share awards, granted on 8 March 2024 under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability

Date of Transaction

8 March 2025 (vesting) and 10 March 2025 (market sale)

Place of Transaction

London Stock Exchange (XLON)

 

Name

(Position)

 

Status

Price (£)

Volume

Aggregated information

Helen Barraclough

(Group General Counsel and Company Secretary)

PDMR

11.441599

3,208 (of which 1,513 were sold and 1,695 retained.)

N/A Single Transaction

Paul Connolly

(President, Global Operations)

PDMR

11.441599

3,373 (of which 1,153 were sold and 2,220 retained.)

N/A Single Transaction

Phil Cowdy

(Chief Corporate Development and Corporate Affairs Officer)

PDMR

11.441599

3,456 (of which 1,630 were sold and 1,826 retained.)

N/A Single Transaction

Craig Gaffin

(President, Global Orthopaedics)

PDMR

11.441599

1,908 (of which 567 were sold and 1,341 retained.)

N/A Single Transaction

Rohit Kashyap (President, Advanced Wound Management and Global Commercial Operations)

PDMR

11.441599

3,778 (of which 1,125 were sold and 2,653 retained)

N/A Single Transaction

Mizanu Kebede

(Chief Quality & Regulatory Affairs Officer)

PDMR

11.441599

3,880 (of which 1,434 were sold and 2,446 retained.)

N/A Single Transaction

Elga Lohler

(Chief HR Officer)

PDMR

11.441599

4,839 (of which 1,927 were sold and 2,912 retained.)

N/A Single Transaction

Vasant Padmanabhan

(President Research & Development ENT)

PDMR

11.441599

4,868 (of which 1,808 were sold and 3,060 retained.)

N/A Single Transaction

Alison Parkes

(Chief Compliance Officer)

PDMR

11.441599

1,875 (of which 885 were sold and 990 retained.)

N/A Single Transaction

Scott Schaffner

(President Sports Medicine)

PDMR

11.441599

6,046 (of which 2,245 were sold and 3,801 retained.)

N/A Single Transaction

All figures in these columns are stated to 6 decimal places where applicable.

 

 

Philip Horner

Group Deputy Company Secretary

Smith & Nephew plc

 

Tel: +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFFEVFILLIE

Related Shares:

Smith & Nephew
FTSE 100 Latest
Value8,558.69
Change-100.16